LEADER 00726nam0-22002651i-450- 001 990007733410403321 035 $a000773341 035 $aFED01000773341 035 $a(Aleph)000773341FED01 035 $a000773341 100 $a20021010d--------km-y0itay50------ba 101 0 $aita 200 1 $aAntitrust policy$eThe Case for Repeal$fDominick T. Armentano 210 $aWashington$cCato Institute$dcopyr. 1986 215 $aXII, 78 p.$d24 cm 676 $a346.07 700 1$aArmentano,$bDominick T.$0278354 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007733410403321 952 $a12-C-124$b542$fDDCP 959 $aDDCP 996 $aAntitrust policy$9666082 997 $aUNINA DB $aGEN01 LEADER 01517nam a2200337 i 4500 001 991002330809707536 005 20020507162713.0 008 991206s1998 us ||| | eng 020 $a0471943533 035 $ab11641666-39ule_inst 035 $aLE02734684$9ExL 040 $aDip.to Studi Giuridici$bita 082 0 $a341.753 100 1 $aBlum, Francoise$0529182 245 10$aState monopolies under EC law /$cFrancoise Blum, Anne Logue 260 $aNew York :$bJ. Wiley,$c1998 300 $axxxviii, 402 p. ;$c25 cm. 490 0 $aWiley series in European law 500 $aInclude riferimenti bibliografici (p. [xvii]-xx) e indice 650 4$aConcorrenza$xDiritto - Unione europea 650 4$aConcorrenza$xPolitica governativa - Unione europea 650 4$aMonopoli di Stato$xDiritto e legislazione - Unione Europea 700 1 $aLogue, Anne$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0735084 907 $a.b11641666$b01-03-17$c02-07-02 912 $a991002330809707536 945 $aLE029 341.75 BLU01.01$g1$i2029000003420$lle029$op$pE163.41$q-$rn$so $t0$u0$v0$w0$x0$y.i12573747$z30-09-03 945 $aLE027 341.00 BLU01.01$cC. 2$g1$i2027000006557$lle027$o-$pE0.00$q-$rl$s- $t0$u1$v0$w1$x0$y.i11863900$z02-07-02 945 $aLE027 341.00 BLU01.01$cC. 1$g1$i2027000019427$lle027$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i11863912$z02-07-02 996 $aState monopolies under EC law$91452066 997 $aUNISALENTO 998 $ale029$a(2)le027$b01-01-99$cm$da $e-$feng$gus $h0$i3 LEADER 07399nam 22003973 450 001 9910880294703321 005 20240609090313.0 010 $a1-4988-4533-9 035 $a(MiAaPQ)EBC31460007 035 $a(Au-PeEL)EBL31460007 035 $a(CKB)32245688000041 035 $a(EXLCZ)9932245688000041 100 $a20240609d2024 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDengue 205 $a2024th ed. 210 1$aLos Angeles :$cGideon Informatics, Incorporated,$d2024. 210 4$dİ2024. 215 $a1 online resource (487 pages) 327 $aIntro -- Copyright -- Introduction: The GIDEON e-book series -- Table of Contents -- Dengue -- Epidemiology -- Agent -- Reservoir -- Vector -- Vehicle -- Incubation Period -- Diagnostic Tests -- Typical Adult Therapy -- Typical Pediatric Therapy -- Vaccine -- Clinical Hints -- Synonyms -- Clinical -- References -- Distribution Map -- Images -- Global status -- References -- Afghanistan -- References -- Albania -- References -- Algeria -- References -- American Samoa -- References -- Andorra -- Angola -- References -- Anguilla -- References -- Antigua and Barbuda -- References -- The Antilles (miscellaneous) -- References -- Argentina -- References -- Armenia -- Aruba -- References -- Australia -- References -- Austria -- References -- Azerbaijan -- The Bahamas -- References -- Bahrain -- Bangladesh -- References -- Barbados -- References -- Belarus -- Belgium -- References -- Belize -- References -- Benin -- References -- Bermuda -- References -- Bhutan -- References -- Bolivia -- References -- Bosnia and Herzegovina -- Brazil -- References -- The British Virgin Islands -- References -- Brunei -- References -- Bulgaria -- Burkina Faso -- References -- Cambodia -- References -- Cameroon -- References -- Canada -- References -- The Canary Islands -- References -- Cape Verde -- References -- The Cayman Islands -- References -- Central African Republic -- References -- Chad -- References -- Chile -- References -- China -- References -- Colombia -- References -- The Comoros and Mayotte -- References -- The Cook Islands -- References -- Costa Rica -- References -- Croatia -- References -- Cuba -- References -- Cyprus -- References -- The Czech Republic -- References -- The Democratic Republic of Congo -- References -- Denmark -- References -- Djibouti -- References -- Dominica -- References -- The Dominican Republic -- References -- Ecuador. 327 $aReferences -- Egypt -- References -- El Salvador -- References -- Equatorial Guinea -- References -- Eritrea -- References -- Estonia -- Ethiopia -- References -- Fiji -- References -- Finland -- References -- France -- References -- French Guiana -- References -- French Polynesia -- References -- Gabon -- References -- Georgia -- References -- Germany -- References -- Ghana -- References -- Gibraltar -- References -- Greece -- References -- Grenada -- References -- Guadeloupe -- References -- Guam -- References -- Guatemala -- References -- Guinea -- References -- Guyana -- References -- Haiti -- References -- Honduras -- References -- Hong Kong -- References -- Hungary -- Iceland -- India -- References -- Indonesia -- References -- Iran -- References -- Iraq -- References -- Ireland -- Israel -- References -- Italy -- References -- Ivory Coast -- References -- Jamaica -- References -- Japan -- References -- Jordan -- Kazakhstan -- Kenya -- References -- Kiribati -- References -- Kosovo -- Kuwait -- References -- Kyrgyzstan -- Laos -- References -- Latvia -- Lebanon -- References -- Liechtenstein -- Lithuania -- Luxembourg -- Macao -- References -- Madagascar -- References -- Malawi -- References -- Malaysia -- References -- The Maldives -- References -- Mali -- References -- Malta -- The Marshall Islands -- References -- Martinique -- References -- Mauritania -- References -- Mauritius -- References -- Mexico -- References -- Micronesia -- References -- Moldova -- References -- Mongolia -- Montenegro -- Montserrat -- References -- Morocco -- References -- Mozambique -- References -- Myanmar -- References -- Namibia -- References -- Nauru -- References -- Nepal -- References -- The Netherlands -- References -- New Caledonia -- References -- New Zealand -- References -- Nicaragua -- References -- Niger -- References -- Nigeria -- References -- Niue. 327 $aReferences -- North Macedonia -- The Northern Marianas -- References -- Norway -- References -- Oman -- References -- Pakistan -- References -- Palau -- References -- Panama -- References -- Papua New Guinea -- References -- Paraguay -- References -- Peru -- References -- The Philippines -- References -- Pitcairn Island -- Poland -- References -- Portugal -- References -- Puerto Rico -- References -- Qatar -- References -- South Korea -- References -- Reunion -- References -- Romania -- References -- The Russian Federation -- References -- Samoa -- References -- San Marino -- Sao Tome and Principe -- References -- Saudi Arabia -- References -- Scotland -- Senegal -- References -- Serbia -- The Seychelles -- References -- Sierra Leone -- References -- Singapore -- References -- Slovakia -- Slovenia -- The Solomon Islands -- References -- Somalia -- References -- South Africa -- References -- South Sudan -- References -- Spain -- References -- Sri Lanka -- References -- Saint Kitts and Nevis -- References -- Saint Lucia -- References -- Saint Vincent and The Grenadines -- References -- Sudan -- References -- Suriname -- References -- Sweden -- References -- Switzerland -- References -- Syria -- References -- Taiwan -- References -- Tajikistan -- Tanzania -- References -- Thailand -- References -- Timor-Leste -- References -- Togo -- References -- Tokelau -- References -- Tonga -- References -- Trinidad and Tobago -- References -- Tunisia -- References -- Turkey -- References -- The Turks and Caicos Islands -- References -- Tuvalu -- References -- Uganda -- References -- Ukraine -- The United Arab Emirates -- References -- The United Kingdom -- References -- The United States -- References -- Uruguay -- References -- Uzbekistan -- Vanuatu -- References -- Venezuela -- References -- Vietnam -- References -- The U.S. Virgin Islands -- References. 327 $aWallis and Futuna Islands -- References -- Yemen -- References -- Zambia -- References -- Vaccines & -- Immunoglobulins -- Dengue - DEV serogroup 2 derived -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for Dengue - DEV serogroup 2 derived (4 listed) -- Contraindications for Dengue - DEV serogroup 2 derived (2 listed) -- Trade names of Dengue - DEV serogroup 2 derived (2 listed) -- Dengue - Yellow-fever derived -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for Dengue - Yellow-fever derived (4 listed) -- Contraindications for Dengue - Yellow-fever derived (3 listed) -- Trade names of Dengue - Yellow-fever derived (1 listed) -- About GIDEON. 700 $aBerger$b Stephen$01210032 701 $aGIDEON science team$b Gideon science$01765422 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910880294703321 996 $aDengue$94207332 997 $aUNINA